Shares of Moderna (NASDAQ: MRNA) were moving higher Monday after the FDA granted full approval for its COVID-19 vaccine, which had previously only had Emergency Use Authorization.
Full Answer
How much is Moderna really worth?
Today, after it developed and delivered one of the fastest-arriving and most effective shots against Covid-19, Moderna’s market value is approaching $100 billion. Some of the stock's 1,000% gain is undoubtedly warranted.
Could Moderna stock help you retire a millionaire?
That's the advice from several financial experts across the country who said that investors shouldn't do anything rash with their 401(k) retirement accounts amid a turbulent 2022 stock ... If you are not maxing out your elective deferrals and can afford ...
Why are Moderna shares down?
With the omicron variant proving to be highly infectious, there is a view among the scientific community, herd immunity could soon be reached, bringing the pandemic to an end. (Get Free Alerts for MRNA) shares were down 2.36% at $205.20. was slipping 2.01% at $198.90.
When will Moderna stock be a screaming buy?
Wall Street expects a year-over-year increase in earnings on higher revenues when Moderna (MRNA) reports results for the quarter ended December 2021.
How much will Moderna cost in 2021?
Last November, I estimated that Moderna’s 2021 revenues could increase about $35 billion thanks to purchases of its Covid-19 vaccine. This assumed that Moderna would make about a billion doses to fulfill orders around the world at an average price of $34.70 — for total 2021 revenue of $34.7 billion. Back then, Moderna was charging $24.80 a shot in the U.S. and between $32 and $37 per dose outside the U.S.
How long does Moderna last?
Moderna suggested that people should get a booster shot before this winter. According to Barron’s, Moderna said its shots are still 92% effective after four months.
When will Moderna start testing?
Moderna -- which had 12 drug candidates under development in May 2020 — is beginning late stage testing of its flu and respiratory syncytial virus vaccines and plans to begin a Phase 3 study of its cytomegalovirus vaccine later in 2021, according to Investor’s Business Daily.
Is Moderna a fast growing company?
While Moderna’s financial guidance for the rest of the year is unquantified, analysts expect fast growth. Moderna’s CFO David Meline said in the earnings conference call that Moderna “expects [its] growth rate to accelerate as the business rapidly expands.”
Did Moderna buy back its stock?
Moderna beat analysts’ expectations for top-line growth in the second quarter and announced a $1 billion stock buyback. According to Investor’s Business Daily Moderna’s $4.35 billion in second quarter sales were about 6,200% higher than the year before and beat expectations by about $250 million. Its earnings per share of $6.46 were 8.4% higher than the consensus.
Is Forbes opinion their own?
Opinions expressed by Forbes Contributors are their own.
Is Moderna signing agreements for 2023?
Moderna is also signing agreements for 2023 "as forward-looking countries prepare for the endemic phase of Covid-19," noted Investor’s Business Daily.
The biotech could help reshape the global vaccine market
Joe honed his investing skills as an analyst for Stock Advisor. He battle-tested his investment philosophy and strategies as portfolio manager of Tier 1, a market-crushing Motley Fool real-money portfolio that delivered 24.58% annualized returns.
What happened
Shares of Moderna ( NASDAQ:MRNA) rose 4.9% to a record closing high of $246.66 on Wednesday, as health officials warned of the potential for another wave of COVID-19 infections later this year.
So what
New coronavirus strains, such as the Delta variant, are spreading rapidly in the U.S. and other parts of the world. They're driving a rebound in COVID-19 case counts in many areas, which is fueling calls for governments to step up their vaccination efforts.
Now what
If COVID-19 booster vaccines turn out to be needed on a regular basis, say annually or even semiannually, they could become a significant source of recurring revenue for Moderna. Additionally, the biotech's coronavirus-related revenue will help fuel its highly regarded research and development program.
What is the metaverse?
Simply put, the metaverse is a virtual world that will harness the power of a collection of nascent technologies, including augmented reality (AR), virtual reality (VR), and video, and allow users to interact in a digital world.
Can dividend stocks outrun inflation?
A carefully selected dividend stock portfolio can outrun inflation. 3 ideas to consider.
What happened
Shares of Moderna (NASDAQ: MRNA) were moving higher Monday after the FDA granted full approval for its COVID-19 vaccine, which had previously only had Emergency Use Authorization.
So what
On Monday morning, the FDA announced its full approval of Moderna's COVID-19 vaccine, which will be marketed under the name Spikevax, saying it meets the regulator's rigorous standards for safety, effectiveness, and manufacturing quality.
Now what
Unlike most growth stocks, Moderna is highly profitable at the moment, and is trading at a cheap price-to-earnings ratio of just 10, though its profits are being inflated in the near term by the booming global demand for COVID-19 vaccines.
The Motley Fool
Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community.
When will Moderna be available in Japan?
In a latest deal, Takeda Pharmaceutical agreed to supply 50 million does of Moderna’s vaccine to Japan. The extra doses could be supplied at the beginning of 2022. Similar deals may follow as more countries open up to the idea of booster doses, which is bullish for Moderna and other vaccine makers.
Is RSI oversold?
Technically, RSI is in the extremely oversold territory, and the risks of a pullback are increasing day by day.
A regulatory action is giving investors a glimpse of its business beyond the pandemic
Jason covers stocks for the Fool. He leans on his consulting background and executive experience in the human capital management and healthcare industries to offer analysis of individual companies.
What happened
Shares of Moderna ( NASDAQ:MRNA) are up 9% as of 2:45 p.m. EDT today, after the Food and Drug Administration (FDA) granted Fast Track designation for mRNA-1345, the company's vaccine candidate for respiratory syncytial virus (RSV).
So what
RSV typically produces cold-like symptoms that last for a week or two. However, it does lead to about 58,000 hospitalizations in young children and 177,000 in older adults every year in the U.S. The agency's designation only applies to people over 60 years old.
Now what
If Moderna can commercialize the drug, it won't have to share the rewards. It owns 100% of the asset. Although the market is estimated at less than $1 billion, the impact could be more substantial. It plans to create a seasonal respiratory vaccine to protect against RSV, COVID-19, and influenza.
